Last 12 months
Inside the activity.
10 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 9 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 1 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 08, 2024 Filed Mar 8, 2024 17:37 UTC |
Evans DaronCFO
|
PurchaseCommon Shares | 50,000 | $1.93 | $96,345.00 |
DisclosureSEC source: 0000912282-24-000232 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,900 F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.83 to $1.95, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any securityholder of Rezolute, Inc. or the staff of the Securities an Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 14:35 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
PurchaseCommon Shares | 500 | $1.85 | $925.00 |
DisclosureSEC source: 0000912282-24-000236 · form4.xml · nonDerivative · entry 1 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Held by minor child Disclosed balance after: 500 Read SEC document |
| March 07, 2024 Filed Mar 14, 2024 14:35 UTC |
Kim Young-JinDirector
|
PurchaseCommon Shares | 36,503 | $1.91 | $69,859.44 |
DisclosureSEC source: 0000912282-24-000249 · form4.xml · nonDerivative · entry 2 Kim Young-Jin · CIK 0001768406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,450 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.8969 to $1.9533, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 07, 2024 Filed Mar 18, 2024 15:19 UTC Amendment |
ROBERTS BRIAN KENNETHChief Medical Officer
|
PurchaseCommon Shares | 500 | $1.85 | $925.00 |
DisclosureSEC source: 0000912282-24-000268 · form4.xml · nonDerivative · entry 1 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Held by minor child Disclosed balance after: 576 Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 13:47 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
PurchaseCommon Shares | 2,000 | $1.70 | $3,400.00 |
DisclosureSEC source: 0000912282-24-000187 · form4.xml · nonDerivative · entry 2 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,552 Read SEC document |
| February 26, 2024 Filed Feb 28, 2024 16:40 UTC |
Elam Nevan CDirector · CEO
|
PurchaseCommon Shares | 5,000 | $1.68 | $8,400.00 |
DisclosureSEC source: 0000912282-24-000189 · form4.xml · nonDerivative · entry 1 Elam Nevan C · CIK 0001314773 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,817 Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 13:47 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
PurchaseCommon Shares | 6,000 | $1.69 | $10,140.00 |
DisclosureSEC source: 0000912282-24-000187 · form4.xml · nonDerivative · entry 1 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,552 F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.69 to $1.6985, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 12:01 UTC |
Evans DaronCFO
|
PurchaseCommon Shares | 4,500 | $1.37 | $6,165.00 |
DisclosureSEC source: 0000912282-24-000163 · form4.xml · nonDerivative · entry 3 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by minor child #3 Disclosed balance after: 4,500 Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 12:01 UTC |
Evans DaronCFO
|
PurchaseCommon Shares | 4,500 | $1.37 | $6,165.00 |
DisclosureSEC source: 0000912282-24-000163 · form4.xml · nonDerivative · entry 2 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by minor child #2 Disclosed balance after: 4,500 Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 12:01 UTC |
Evans DaronCFO
|
PurchaseCommon Shares | 41,900 | $1.30 | $54,411.34 |
DisclosureSEC source: 0000912282-24-000163 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,900 F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.17 to $1.39, inclusive. The reporting person undertakes to provide to Rezolute, Inc.., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 16:55 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
PurchaseCommon Shares | 7,000 | $1.31 | $9,142.00 |
DisclosureSEC source: 0000912282-24-000172 · form4.xml · nonDerivative · entry 1 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,552 F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.295 to $1.320, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 17:36 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0000912282-24-000085 · form4.xml · derivative · entry 1 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Shares · 130,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: The options vest in 36 equal monthly installments, beginning February 23, 2024. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 17:47 UTC |
Evans DaronCFO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0000912282-24-000089 · form4.xml · derivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Shares · 275,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: The options were granted on January 23, 2024, and shall vest as follows: One-fourth (1/4) on the one-year anniversary of the grant date and one thirty-sixth (1/36) of the remaining options shall vest on the same day of each month thereafter until the option is 100% vested. The unvested portion of the option will not be exercisable on or after the Reporting Person's termination of Continuous Service subject to the terms of the Reporting Person's employment agreement. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 17:33 UTC |
Elam Nevan CDirector · CEO
|
GrantEmployee Stock Options (Right to Buy) · Derivative | 340,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0000912282-24-000083 · form4.xml · derivative · entry 1 Elam Nevan C · CIK 0001314773 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 340,000 Underlying: Common Shares · 340,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: The options vest in 36 equal monthly installments, beginning February 23, 2024. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 12:08 UTC |
Labrucherie Gil MDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0000912282-24-000079 · form4.xml · derivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2034-01-23 F1 · derivative.exercise_date: The options vest in 36 equal monthly installments, beginning February 23, 2024. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 17:10 UTC |
Hogenhuis WladimirDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0000912282-24-000081 · form4.xml · derivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2034-01-23 F1 · derivative.exercise_date: The options vest in 36 equal monthly installments, beginning February 23, 2024. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 17:06 UTC |
FAUCHET PHILIPPEDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0000912282-24-000077 · form4.xml · derivative · entry 1 FAUCHET PHILIPPE · CIK 0001824260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2034-01-23 F1 · derivative.exercise_date: The options vest in 36 equal monthly installments, beginning February 23, 2024. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 17:04 UTC |
KREHER NERISSADirector
|
GrantDirector Stock Options (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0000912282-24-000075 · form4.xml · derivative · entry 1 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2034-01-23 F1 · derivative.exercise_date: The options vest in 36 equal monthly installments, beginning February 23, 2024. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 15:18 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
PurchaseCommon Shares | 5,000 | $1.90 | $9,499.50 |
DisclosureSEC source: 0000912282-23-000162 · form4.xml · nonDerivative · entry 1 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,552 Read SEC document |
| July 22, 2022 Filed Mar 14, 2024 14:35 UTC |
Kim Young-JinDirector
|
PurchaseCommon Shares | 78,947 | $3.80 | $299,998.60 |
DisclosureSEC source: 0000912282-24-000249 · form4.xml · nonDerivative · entry 1 Kim Young-Jin · CIK 0001768406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,947 Read SEC document |
| July 22, 2022 Filed Mar 19, 2024 19:47 UTC |
HANDOK, INC.Director · 10% owner
|
PurchaseCommon Shares | 3,157,895 | $3.80 | $12,000,001.00 |
DisclosureSEC source: 0000912282-24-000283 · form4.xml · nonDerivative · entry 2 HANDOK, INC. · CIK 0001798101 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,942,617 Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 22:12 UTC |
ROBERTS BRIAN KENNETHSr VP, Clinic Development
|
GrantStock Option (right to buy) · Derivative | 700,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001567619-22-013416 · doc1.xml · derivative · entry 1 ROBERTS BRIAN KENNETH · CIK 0001829608 · Sr VP, Clinic Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: This Option shall vest and become exercisable as follows: one fourth (1/4) of such Options shall vest on the one year anniversary of the Grant date and one thirty-sixth (1/36) of the remaining Options shall vest on the same day of each month thereafter until the Option is 100% vested. The unvested portion of the Option will not be exercisable on or after the Reporting Person's termination of Continuous Service. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 21:56 UTC |
Elam Nevan CDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 2,600,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001567619-22-013411 · doc1.xml · derivative · entry 1 Elam Nevan C · CIK 0001314773 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600,000 Underlying: Common Stock · 2,600,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: This Option shall vest and become exercisable as follows: one fourth (1/4) of such Options shall vest on the one year anniversary of the Grant date and one thirty-sixth (1/36) of the remaining Options shall vest on the same day of each month thereafter until the Option is 100% vested. The unvested portion of the option will not be exercisable on or after the Reporting Person's termination of Continuous Service subject to the terms of the Reporting Person's employment agreement. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 17:43 UTC |
Labrucherie Gil MDirector
|
GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001567619-22-013409 · doc1.xml · derivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: The Option will become vested and exercisable as follows: one thirty-sixth (1/36) of such Option shall vest on the first day of the month following the Grant Date and each month thereafter on the first day of each month until the Option is 100% vested. The unvested portion of the Option will not be exercisable on or after the Director's termination of Continuous Service. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 22:19 UTC |
FAUCHET PHILIPPEDirector
|
GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001567619-22-013418 · doc1.xml · derivative · entry 1 FAUCHET PHILIPPE · CIK 0001824260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: The Option will become vested and exercisable as follows: one thirty-sixth (1/36) of such Option shall vest on the first day of the month following the Grant Date and each month thereafter on the first day of each month until the Option is 100% vested. The unvested portion of the Option will not be exercisable on or after the Director's termination of Continuous Service. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 22:08 UTC |
Hogenhuis WladimirDirector
|
GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001567619-22-013413 · doc1.xml · derivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: The Option will become vested and exercisable as follows: one thirty-sixth (1/36) of such Option shall vest on the first day of the month following the Grant Date and each month thereafter on the first day of each month until the Option is 100% vested. The unvested portion of the Option will not be exercisable on or after the Director's termination of Continuous Service. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 21:30 UTC |
KREHER NERISSADirector
|
GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001567619-22-013407 · doc1.xml · derivative · entry 1 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: The Option will become vested and exercisable as follows: one thirty-sixth (1/36) of such Options shall vest on the first day of the month following Grant Date and each month thereafter on the first day of each month [until the Option is 100% vested. The unvested portion of the Option will not be exercisable on or after the Director's termination of Continuous Service. Read SEC document |
| June 23, 2022 Filed Jun 28, 2022 14:15 UTC |
Kim Young-JinDirector
|
GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001567619-22-013426 · doc1.xml · derivative · entry 1 Kim Young-Jin · CIK 0001768406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: The Option will become vested and exercisable as follows: one thirty-sixth (1/36) of such Option shall vest on the first day of the month following the Grant Date and each month thereafter on the first day of each month until the Option is 100% vested. The unvested portion of the Option will not be exercisable on or after the Director's termination of Continuous Service. Read SEC document |
| May 19, 2022 Filed May 19, 2022 19:13 UTC |
ROBERTS BRIAN KENNETHSr VP, Clinic Development
|
PurchaseCommon Stock | 300 | $2.95 | $883.77 |
DisclosureSEC source: 0001567619-22-011253 · doc1.xml · nonDerivative · entry 3 ROBERTS BRIAN KENNETH · CIK 0001829608 · Sr VP, Clinic Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,552 Read SEC document |
| May 18, 2022 Filed May 19, 2022 19:13 UTC |
ROBERTS BRIAN KENNETHSr VP, Clinic Development
|
PurchaseCommon Stock | 200 | $2.86 | $571.98 |
DisclosureSEC source: 0001567619-22-011253 · doc1.xml · nonDerivative · entry 2 ROBERTS BRIAN KENNETH · CIK 0001829608 · Sr VP, Clinic Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,252 Read SEC document |
| May 17, 2022 Filed May 19, 2022 19:13 UTC |
ROBERTS BRIAN KENNETHSr VP, Clinic Development
|
PurchaseCommon Stock | 1,000 | $3.41 | $3,406.50 |
DisclosureSEC source: 0001567619-22-011253 · doc1.xml · nonDerivative · entry 1 ROBERTS BRIAN KENNETH · CIK 0001829608 · Sr VP, Clinic Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,052 Read SEC document |
| May 04, 2022 Filed May 6, 2022 21:18 UTC |
ROBERTS BRIAN KENNETHSr VP, Clinic Development
|
PurchaseCommon Stock | 21,052 | $3.80 | $79,997.60 |
DisclosureSEC source: 0001567619-22-009701 · doc1.xml · nonDerivative · entry 1 ROBERTS BRIAN KENNETH · CIK 0001829608 · Sr VP, Clinic Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,052 F1 · kind: The Reporting Person acquired these shares of common stock in connection with the Issuer's closing of registered direct public offering on May 4, 2022. Read SEC document |
| May 04, 2022 Filed May 6, 2022 17:15 UTC |
Labrucherie Gil MDirector
|
PurchaseCommon Stock | 52,631 | $3.80 | $199,997.80 |
DisclosureSEC source: 0001567619-22-009699 · doc1.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,631 F1 · kind: The Reporting Person acquired these shares of common stock in connection with the Issuer's closing of registered direct public offering on May 4, 2022. Read SEC document |
| May 04, 2022 Filed May 6, 2022 21:14 UTC |
Hogenhuis WladimirDirector
|
PurchaseCommon Stock | 25,000 | $3.80 | $95,000.00 |
DisclosureSEC source: 0001567619-22-009698 · doc1.xml · nonDerivative · entry 2 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,693 F1 · kind: The Reporting Person acquired these shares of common stock in connection with the Issuer's closing of registered direct public offering on May 4, 2022. Read SEC document |
| May 04, 2022 Filed May 9, 2022 16:28 UTC Amendment |
Labrucherie Gil MDirector
|
PurchaseCommon Stock | 52,631 | $3.80 | $199,997.80 |
DisclosureSEC source: 0001567619-22-009789 · doc1.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · The Labrucherie Trust dated 9/1/2009 Disclosed balance after: 53,572 F1 · kind: The Reporting Person acquired these shares of common stock in connection with the Issuer's closing of registered direct public offering on May 4, 2022. F2 · balance_after: Issuer effected a 50:1 reverse stock split on October 9, 2020. Reporting Person's indirect holdings following the split were 941 shares. Read SEC document |
| October 15, 2021 Filed May 6, 2022 21:14 UTC |
Hogenhuis WladimirDirector
|
PurchaseCommon Stock | 7,693 | $6.50 | $50,004.50 |
DisclosureSEC source: 0001567619-22-009698 · doc1.xml · nonDerivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,693 Read SEC document |
| October 15, 2021 Filed Mar 19, 2024 19:47 UTC |
HANDOK, INC.Director · 10% owner
|
PurchaseCommon Shares | 769,231 | $6.50 | $5,000,001.50 |
DisclosureSEC source: 0000912282-24-000283 · form4.xml · nonDerivative · entry 1 HANDOK, INC. · CIK 0001798101 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,784,722 Read SEC document |
| June 14, 2021 Filed Jul 15, 2021 01:00 UTC |
ROBERTS BRIAN KENNETHSr VP, Clinic Development
|
Disposition to issuerStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001567619-21-013435 · doc1.xml · derivative · entry 3 ROBERTS BRIAN KENNETH · CIK 0001829608 · Sr VP, Clinic Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2029-07-31 F2 · derivative.exercise_date: The disposed of options only vest equally over a 36-month period following certain performance and market price criteria, which had not been met through date of disposition. Read SEC document |
| June 14, 2021 Filed Jul 15, 2021 01:00 UTC |
ROBERTS BRIAN KENNETHSr VP, Clinic Development
|
Disposition to issuerStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $52.50 | $0.00 |
DisclosureSEC source: 0001567619-21-013435 · doc1.xml · derivative · entry 2 ROBERTS BRIAN KENNETH · CIK 0001829608 · Sr VP, Clinic Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9 shares Expires 2027-04-13 Read SEC document |
| June 14, 2021 Filed Jul 15, 2021 01:00 UTC |
ROBERTS BRIAN KENNETHSr VP, Clinic Development
|
GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $12.28 | $0.00 |
DisclosureSEC source: 0001567619-21-013435 · doc1.xml · derivative · entry 1 ROBERTS BRIAN KENNETH · CIK 0001829608 · Sr VP, Clinic Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: The Option will become vested and exercisable as follows: (i) 25% of options shall vest on Grant date and (ii) one thirty-sixth (1/36) of remaining such Options shall vest each month thereafter on the first day of each month until the Option is 100% vested. The unvested portion of the Option will not be exercisable on or after the Reporting Person's termination of Continuous Service. Read SEC document |
| June 14, 2021 Filed Jul 15, 2021 00:55 UTC |
Elam Nevan CDirector · Chief Executive Officer
|
Disposition to issuerStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001567619-21-013433 · doc1.xml · derivative · entry 4 Elam Nevan C · CIK 0001314773 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575,000 Underlying: Common Stock · 100,000 shares Expires 2029-07-31 F2 · derivative.exercise_date: The disposed of options only vest equally over a 36-month period following certain performance and market price criteria, which had not been met through date of disposition. F3 · balance_after: The number of derivative securities beneficially owned is based on post-split stock numbers. Read SEC document |
| June 14, 2021 Filed Jul 15, 2021 00:55 UTC |
Elam Nevan CDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 375,000 | $0.00 Strike: $12.28 | $0.00 |
DisclosureSEC source: 0001567619-21-013433 · doc1.xml · derivative · entry 3 Elam Nevan C · CIK 0001314773 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675,000 Underlying: Common Stock · 675,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: This Option shall vest and become exercisable as follows: (i) 25% of the options shall vest on the Grant Date and (ii) one thirty-sixth (1/36) of such Options shall vest each month thereafter on the first day of each month until the Option is 100% vested. The unvested portion of the option will not be exercisable on or after the Reporting Person's termination of Continuous Service subject to the terms of the Reporting Person's employment agreement. F3 · balance_after: The number of derivative securities beneficially owned is based on post-split stock numbers. Read SEC document |
| June 14, 2021 Filed Jul 15, 2021 00:55 UTC |
Elam Nevan CDirector · Chief Executive Officer
|
Disposition to issuerStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $60.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013433 · doc1.xml · derivative · entry 2 Elam Nevan C · CIK 0001314773 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires 2026-12-28 Read SEC document |
| June 14, 2021 Filed Jul 15, 2021 00:55 UTC |
Elam Nevan CDirector · Chief Executive Officer
|
Disposition to issuerStock Option (right to buy) · Derivative | 34,800 | $0.00 Strike: $103.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013433 · doc1.xml · derivative · entry 1 Elam Nevan C · CIK 0001314773 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,800 shares Expires 2025-02-23 Read SEC document |
| June 14, 2021 Filed Jul 14, 2021 21:03 UTC |
Labrucherie Gil MDirector
|
GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $12.28 | $0.00 |
DisclosureSEC source: 0001567619-21-013437 · doc1.xml · derivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: This option will become vested and exercisable as follows: one thirty-sixth (1/36) of such Options shall vest on the first day of the month following the Grant Date and each month thereafter on the first day of each month until the Option is 100% vested. The unvested portion of the Option will not be exercisable on or after the Director's termination of Continuous Service. Read SEC document |
| June 14, 2021 Filed Jul 15, 2021 01:11 UTC |
Hogenhuis WladimirDirector
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $12.28 | $0.00 |
DisclosureSEC source: 0001567619-21-013443 · doc1.xml · derivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: The Option will become vested and exercisable as follows: one thirty-sixth (1/36) of such Options shall vest on the first day of the month following Grant Date and each month thereafter on the first day of each month until the Option is 100% vested. The unvested portion of the Option will not be exercisable on or after the Director's termination of Continuous Service. Read SEC document |
| June 14, 2021 Filed Jul 15, 2021 01:08 UTC |
FAUCHET PHILIPPEDirector
|
GrantStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $12.28 | $0.00 |
DisclosureSEC source: 0001567619-21-013441 · doc1.xml · derivative · entry 1 FAUCHET PHILIPPE · CIK 0001824260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: The Option will become vested and exercisable as follows: one thirty-sixth (1/36) of such Option shall vest on the first day of the month following the Grant Date and each month thereafter on the first day of each month until the Option is 100% vested. The unvested portion of the Option will not be exercisable on or after the Director's termination of Continuous Service. Read SEC document |
| June 14, 2021 Filed Jul 15, 2021 01:05 UTC |
KREHER NERISSADirector
|
GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $12.28 | $0.00 |
DisclosureSEC source: 0001567619-21-013439 · doc1.xml · derivative · entry 1 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: The Option will become vested and exercisable as follows: one thirty-sixth (1/36) of such Options shall vest on the first day of the month following Grant Date and each month thereafter on the first day of each month [until the Option is 100% vested. The unvested portion of the Option will not be exercisable on or after the Director's termination of Continuous Service. Read SEC document |
| June 14, 2021 Filed Aug 31, 2021 18:02 UTC Amendment |
Elam Nevan CDirector · Chief Executive Officer
|
Disposition to issuerStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001567619-21-016495 · doc1.xml · derivative · entry 4 Elam Nevan C · CIK 0001314773 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 575,000 Underlying: Common Stock · 100,000 shares Expires 2029-07-31 F2 · derivative.exercise_date: The disposed of options only vest equally over a 36-month period following certain performance and market price criteria, which had not been met through date of disposition. F3 · balance_after: The number of derivative securities beneficially owned is based on post-split stock numbers. Read SEC document |
| June 14, 2021 Filed Aug 31, 2021 18:02 UTC Amendment |
Elam Nevan CDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 375,000 | $0.00 Strike: $12.28 | $0.00 |
DisclosureSEC source: 0001567619-21-016495 · doc1.xml · derivative · entry 3 Elam Nevan C · CIK 0001314773 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675,000 Underlying: Common Stock · 675,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: This Option shall vest and become exercisable as follows: one thirty-sixth (1/36) of such Options shall vest on the first date of the month following the Grant Date and each month thereafter on the first date of each month until the Option is 100% vested. The unvested portion of the option will not be exercisable on or after the Reporting Person's termination of Continuous Service subject to the terms of the Reporting Person's employment agreement. F3 · balance_after: The number of derivative securities beneficially owned is based on post-split stock numbers. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.